creating knowledge for future



High Quality


Scholarly Publishing
                CAREER NETWORK  
         
World's one of the largest Research
Career Network
Benefits
  •     Academic & Industry jobs
  •     Project funding
  •     Visiting faculty positions
  •     Visiting scientist positions
  •     Invited talks
  •     and more...  
   
Register FREE  
 
 
 
 
 
  Global Journal of Biochemistry. Volume 2, Issue 4 (2011) pp. 250-261
  Review Article Free Article
 
Dysregulation of mTOR pathway component in breast cancer and mTOR inhibitors in breast cancer therapy
  Jun Lin, Xiaochun Bai  
     
Department of Cell Biology, School of Basic Medical Science, Southern Medical University Guangzhou 510515, China
   
  Abstract  
  In breast cancer, the phosphatidylinositol 3-kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can be activated by several membrane receptors, including the human epidermal growth factor receptor (HER) family, the insulin-like growth factor (IGF) receptor, and the estrogen receptor (ER), thus plays a critical role in tumorigenesis, progression and development of endocrine resistance. mTOR, the central modulator of this pathway, gained increasing more attention as a potent anti-cancer target. In this review, we summarize the dysregulation of key components of mTOR pathway in breast cancer and their prognostic values, and the clinical application of mTOR inhibitors, with special emphasis on the latest achievement in the recent years.
     
  Keywords  
  Mammalian target of rapamycin; Breast cancer  
     
   
   
   
   
     

  © 2016 Cognizure